Home › Enanta Announces SVR12 Results Of 95% From AbbVie's GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1
 

Keywords :   


Enanta Announces SVR12 Results Of 95% From AbbVie's GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1

2015-06-03 06:35:57| drugdiscoveryonline Home Page

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan

Tags: c results study japanese

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05PCMC addresses latest printing trends at \'Power Packs Live\'
13.05More than 50 sessions scheduled for drupa cube
13.05IDENTCO highlights automation and PCB labeling at PCB East
13.05INDA, AFS Partner on FiltXPO 2025 Conference Program
13.05Bell adds 14,174 net retail IPTV subscribers in 1Q 2024
13.05Reynders chooses Vetaphone for surface treatment
13.05Polyvel Makes Organizational Changes
13.05Sun Chemical receives FTA Excellence in Flexography Award
More »